80937-20-8

Basic information

• Product Name: (E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid
• Synonyms: (E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid
• CAS NO: 80937-20-8
• Molecular Formula: C₁₀H₆Cl₂O₃
• Molecular Weight: 245.06
• Mol File: 80937-20-8.mol

Chemical Properties

• Boiling Point: 425.5°C at 760 mmHg
• Flash Point: 211.1°C
• Appearance: /
• Density: 1.475g/cm³
• Vapor Pressure: 5.36E-08mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: (E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid(80937-20-8)
• EPA Substance Registry System: (E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid(80937-20-8)

Safety Data

• Hazardous Substances Data: 80937-20-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid is used as an intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and reactivity. Its ability to be incorporated into the development of new drugs makes it a valuable compound in the pharmaceutical industry.
Used in Organic Chemistry:
In the field of organic chemistry, (E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid serves as a key building block for the creation of more complex organic molecules. Its versatility in reactions and potential to form diverse products positions it as an important compound for research and development in this field.
Used in Antimicrobial and Antifungal Applications:
(E)-4-(3,4-dichlorophenyl)-4-oxo-but-2-enoic acid is also used as a potential agent in the development of antimicrobial and antifungal products. Its chemical properties may contribute to the inhibition of microbial growth, making it a candidate for use in the medical and agricultural industries to combat infections and protect crops.

InChI:InChI=1/C10H6Cl2O3/c11-7-2-1-6(5-8(7)12)9(13)3-4-10(14)15/h1-5H,(H,14,15)/b4-3+

Upstream product

• 2642-63-9 3',4'-dichloroacetophenone 
• 563-96-2 2,2-dihydroxyacetic acid 
• 298-12-4 Glyoxilic acid 
• 108-31-6 maleic anhydride 
• 95-50-1 1,2-dichloro-benzene 
• 6000-59-5 glyoxalic acid monohydrate 

Downstream Products

• 399557-34-7 2-[6-(4-chloro-phenyl)-4-(2,4-dimethoxy-phenyl)-6H-[1,3]thiazin-2-ylamino]-4-(3,4-dichloro-phenyl)-4-oxo-butyric acid 
• 650634-93-8 4-(3,4-dichlorophenyl)-4-oxo-2-(4-antipyrinyl)butanoic acid 
• 1322745-60-7 3-cyano-6-(3,4-dichlorophenyl)-2-methylisonicotinic acid 
• 191015-02-8 4-(3,4-dichloro-phenyl)-4-oxo-but-2-enoic acid 
• 1429427-97-3 C₁₆H₁₁Cl₂NO₂ 
• 1415480-64-6 C₁₈H₁₉Cl₂NO₄ 
• 1415480-48-6 C₁₈H₁₇Cl₂NO₄ 
• 276684-09-4 β-(3,4-dichlorobenzoyl)-α-(phenylthio)propionohydrazide 

Relevant articles and documents

Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents

A series of novel (E)-4-oxo-2-crotonamide derivatives were designed and synthesized to find potent antituberculosis agents. All the target compounds were evaluated for their in vitro activity against Mycobacterium tuberculosis H37Rv(MTB). Results reveal that 4-phenyl moiety at part A and short methyl group at part C were found to be favorable. Most of the derivatives displayed promising activity against MTB with MIC ranging from 0.125 to 4 μg/mL. Especially, compound IIIa16 was found to have the best activity with MIC of 0.125 μg/mL against MTB and with MIC in the range of 0.05–0.48 μg/mL against drug-resistant clinical MTB isolates.

(E)-4-Aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: Design, antiproliferative activity and inhibition of tubulin polymerization

Antiproliferative activity of twenty-nine (E)-4-aryl-4-oxo-2-butenoic acid amides against three human tumor cell lines (HeLa, FemX, and K562) is reported. Compounds showed antiproliferative activity in one-digit micromolar to submicromolar concentrations.

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising the same and methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are de

A simple, diversity oriented synthesis of highly substituted pyridines

Figure represented. A particularly straightforward and efficient protocol for the synthesis of highly substituted pyridines, based on a condensation reaction of β-aminocrotonitrile and easily accessible (E)-2-oxo-4-aryl-but- 3-enoic acids and (E)-4-oxo-4-

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

The present invention relates to compounds of general formula [in-line-formulae]R—Z1—Z2—Z3—R1, ??(I)[/in-line-formulae] wherein R, R1 and Z1 to Z3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

4-phenyl-4-oxo-2-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity

PCT No. PCT/EP96/04517 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/17316 PCT Pub. Date May 15, 19974-Phenyl-4-oxo-butenoic acid derivatives for use in the treatment of the human or animal body by therapy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enzyme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butenoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.

Gastric anti-secretory, anti-ulcer and cytoprotective properties of substituted (E)-4-phenyl- and heteroaryl-4-oxo-2-butenoic acids

A class of anti-secretory, anti-ulcer and cytoprotective agents, the substituted (E)-4-phenyl and heteroaryl-4-oxo-2-butenoic acids, is described.This chemical structure is not related to those of any known anti-cholinergic drugs, histamine H2-receptor antagonists or prostaglandins.Five compounds, 4-(2-methoxyphenyl)- 15, 4-(4-methoxyphenyl)- 22, 4-(3,4-dimethoxyphenyl)- 32, 4-(3,4,5-trimethoxyphenyl)- 40, and 4-(2-furanyl)-4-oxo-2-butenoic acid 44, have cytoprotective activity at a very low dose (0.6 mg/kg, p.o.) and anti-secretory and anti-ulcer activities at higher doses.One of these compounds, RU 38086 40, has been selected for clinical evaluation.Keywords - anti-ulcer agents / cytoprotective agents / (E)-4-phenyl- and heteroaryl-4-oxo-2-butenoic acids.

Gastro-protecting activity

Diseases and ailments accompanied by gastric and gastroduodenal lesions treated by administering a compound of the formula (I) STR1 in which R represents hydrogen or alkyl containing 1 to 5 carbon atoms and R1 and R2, identical or different, both represent alkoxy containing 1 to 3 carbon atoms, or both represent halogen, or R1 represents hydrogen and R2 represents halogen, nitro or trifluoromethyl, or R1 and R2 form a methylenedioxy group at adjacent carbon atoms, as well as pharmaceutically acceptable salts thereof, particularly alkali metal, alkaline earth metal, or amine salts of said acid.